skip to main content

S. 64 (116th): Preserve Access to Affordable Generics and Biosimilars Act

Call or Write Congress

A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

The bill’s titles are written by its sponsor.

Sponsor and status

Amy Klobuchar

Sponsor. Senior Senator for Minnesota. Democrat.

Read Text »
Last Updated: Jan 9, 2019
Length: 20 pages
Introduced
Jan 9, 2019
116th Congress (2019–2021)
Status
Died in a previous Congress

This bill was introduced on January 9, 2019, in a previous session of Congress, but it did not receive a vote.

Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).

Cosponsors

7 Cosponsors (4 Republicans, 3 Democrats)

See Instead

H.R. 2375 (same title)
Ordered Reported — Apr 30, 2019

Source

Position statements

What legislators are saying

Distribution of checks begins after end of DOB stalemate
    — Rep. Garret Graves [R-LA6] on Jul 9, 2019

Two Central Oregon Irrigation Districts, joined by U.S. Senator Jeff Merkley and NRCS Chief Matthew Lohr, celebrate key milestones in $50 million project upgrading rural infrastructure, serving as national model for protecting farms and water resources
    — Sen. Jeff Merkley [D-OR] on Mar 20, 2019

House Judiciary Unanimously Passes Bipartisan Bills to Lower Prescription Drug Prices
    — Rep. Jerrold Nadler [D-NY10] on Apr 30, 2019

More statements at ProPublica Represent...

History

Jan 9, 2019
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

S. 64 (116th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Bills numbers restart every two years. That means there are other bills with the number S. 64. This is the one from the 116th Congress.

This bill was introduced in the 116th Congress, which met from Jan 3, 2019 to Jan 3, 2021. Legislation not passed by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 64 — 116th Congress: Preserve Access to Affordable Generics and Biosimilars Act.” www.GovTrack.us. 2019. September 16, 2021 <https://www.govtrack.us/congress/bills/116/s64>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.